Brussels Stock Exchange

Hyloris to Report 2023 Full-Year Results on 14 March 2024

Retrieved on: 
Friday, March 8, 2024

Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET.

Key Points: 
  • Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET.
  • Following the release, the company will host a live webcast to discuss 2023 results and the outlook for 2024.
  • Participants will have a chance to interact with Stijn Van Rompay, CEO and Jean-Luc Vandebroek, CFO in a question-and-answer session.
  • The details of the event are below:

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Retrieved on: 
Thursday, March 7, 2024

Leuven, BELGIUM – March 07, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Key Points: 
  • Leuven, BELGIUM – March 07, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
    Oxurion received a transparency notification on March 06, 2024, from Atlas Special Opportunities, LLC indicating that as of March 01, 2024, it held 904,304,366 shares of the then outstanding 5,753,951,723 shares, and therefore crossed above the threshold (15%) by virtue of the purchase of voting securities.
  • See Annex 1.

Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up

Retrieved on: 
Tuesday, March 5, 2024

Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 300,000 in the framework of the Atlas Funding Program.

Key Points: 
  • Leuven, BELGIUM, 05 March – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 300,000 in the framework of the Atlas Funding Program.
  • On March 4, 2024, the Company issued the Tenth Tranche consisting of 12 convertible bonds, for an aggregate amount of EUR 300,000.
  • This tranche has been issued in accordance with the agreement reached with Atlas end of 2023, as further described in the press release issued by the Company on December 28, 2023.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Retrieved on: 
Monday, March 4, 2024

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.
  • Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 5,753,951,723 outstanding ordinary shares carrying voting rights (compared to 4,938,734,332 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024

Retrieved on: 
Wednesday, February 28, 2024

Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024

Key Points: 
  • Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024
    Ghent, Belgium – 28 February 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the late-breaking abstract including data from the RED DESERT and SAHARA proof-of-concept studies of the Company’s DSR therapy in patients with diuretic-resistant heart failure have been selected for a late-breaking presentation at THT 2024 .
  • Technology and Heart failure Therapeutics (THT) will be held from March 4th to 6th, 2024 in Boston, US and is an international conference on the latest heart failure innovations, focusing on device- and technology-based treatments within the context of drug therapies.
  • The abstract “Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance” will be presented on Wednesday March 6th, 2024 by Dr. Jeffrey Testani, Associate Professor of Medicine and Director of Heart Failure Research at Yale University School of Medicine and will become available on the website of THT prior to the start of the conference.

Public Storage Declares First Quarter 2024 Dividends

Retrieved on: 
Friday, February 23, 2024

Public Storage (NYSE:PSA) announced today that on February 23, 2024, our Board of Trustees declared a regular quarterly common dividend of $3.00 per common share.

Key Points: 
  • Public Storage (NYSE:PSA) announced today that on February 23, 2024, our Board of Trustees declared a regular quarterly common dividend of $3.00 per common share.
  • The Board also declared dividends with respect to our various series of preferred shares.
  • All the dividends are payable on March 28, 2024, to shareholders of record as of March 13, 2024.
  • Public Storage, a member of the S&P 500 and FT Global 500, is a REIT that primarily acquires, develops, owns, and operates self-storage facilities.

Celyad Oncology announces intention to terminate SEC reporting obligations

Retrieved on: 
Thursday, February 8, 2024

MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission (the “SEC”) to terminate its SEC reporting obligations under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Key Points: 
  • MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission (the “SEC”) to terminate its SEC reporting obligations under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
  • Upon filing of the Form 15F, the Company’s SEC reporting obligations will be immediately suspended, and the Company will not be required to file an Annual Report on Form 20-F for the 2023 fiscal year ending on December 31, 2023.
  • The Company will maintain the listing of its ordinary shares on Euronext Brussels and Euronext Paris.
  • The Company reserves the right, for any reason, to delay the Form 15F filing, to withdraw the filing prior to effectiveness, and to otherwise change its plans in respect of deregistration and termination of its reporting obligations under applicable U.S. federal securities laws in any way.

SEQUANA MEDICAL ANNOUNCES EUR 3.0 MILLION CONVERTIBLE FINANCING FROM MAJOR SHAREHOLDERS AND AGREEMENT WITH LENDERS ON DEFERRAL OF DEBT SERVICE PAYMENTS

Retrieved on: 
Thursday, February 8, 2024

As a result, the Company will significantly reduce its cash burn and halt all European commercial activities whilst maintaining the CE mark.

Key Points: 
  • As a result, the Company will significantly reduce its cash burn and halt all European commercial activities whilst maintaining the CE mark.
  • In addition, the randomized phase of the DSR MOJAVE study will start after alfapump PMA approval.
  • These actions are forecast to significantly reduce the cash requirements through to the end of 2024 by approximately EUR 9.0 million.
  • Through focusing on those activities needed for alfapump FDA approval, we optimize Sequana's ability to deliver on our goals and generate substantial value to all our shareholders.

Mithra updates on cash position

Retrieved on: 
Tuesday, February 6, 2024

Liege, Belgium, 6 February 2024 – 07:00 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.

Key Points: 
  • Liege, Belgium, 6 February 2024 – 07:00 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today provides an update on its current cash position and its plans to address its runway and creating and optimizing value for all its stakeholders.
  • As of today, Mithra has sufficient cash through early March.
  • As a result, Mithra has entered discussions with its secured lenders to extend its cash runway.
  • Mithra will also be approaching existing and new investors and take other cash preservation measures.

Public Storage to Release Fourth Quarter 2023 Earnings Results and Host Quarterly Conference Call

Retrieved on: 
Wednesday, January 31, 2024

Public Storage, a member of the S&P 500 and FT Global 500, is a REIT that primarily acquires, develops, owns, and operates self-storage facilities.

Key Points: 
  • Public Storage, a member of the S&P 500 and FT Global 500, is a REIT that primarily acquires, develops, owns, and operates self-storage facilities.
  • At September 30, 2023, we had: (i) interests in 3,028 self-storage facilities located in 40 states with approximately 217 million net rentable square feet in the United States and (ii) a 35% common equity interest in Shurgard Self Storage Limited (Euronext Brussels:SHUR), which owned 267 self-storage facilities located in seven Western European nations with approximately 15 million net rentable square feet operated under the Shurgard® brand.
  • Our headquarters are located in Glendale, California.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240131003404/en/